Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
|Articles|April 11, 2012
CMS Posts Stage 2 Clinical Quality Measures
Advertisement
Health information technology users, developers, and others wanting to review or comment on the clinical quality measures in the Stage 2 meaningful-use criteria have them now laid out in a handy, downloadable spreadsheet format.
Read the full story:
Source: ModernHealthcare.com
The CMS posted the measures and descriptions about them—one sheet for hospitals and another sheet for office-based physicians and other eligible professionals—on its website.
Advertisement
Related to this article
The opening session of AAO 2026 featured a keynote speech discussing how artificial intelligence (AI) will play a part in health care.
Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.
A meta-analysis found teleophthalmology satisfaction comparable to in-person eye care, but showed a gap between recommending it and reusing it.
Michael Mina, MD, PhD, explains which adverse events drove VYD2311's edge vs an mRNA COVID-19 vaccine and who may benefit most.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
3
Multi-Hit TP53 Linked to Shorter Survival in Chronic-Phase MPN Cohorts
4
Full POLARGO Data Reveal OS, Safety for Pola-R-GemOx in DLBCL
5